FPC
LGND icon

Falcon Point Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Falcon Point Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,602
Closed -$321K – 52
2020
Q2 		$321K Sell
4,602
-6,499
-59% -$412K 1.57% 27
2020
Q1 		$504K Sell
11,101
-1,907
-15% -$108K 1.09% 30
2019
Q4 		$846K Sell
13,008
-39,612
-75% -$2.65M 1.08% 30
2019
Q3 		$3.57M Buy
52,620
+2,715
+5% +$170K 1.96% 21
2019
Q2 		$3.55M Buy
49,905
+1,005
+2% +$74K 1.91% 22
2019
Q1 		$3.83M Buy
48,900
+10,667
+28% +$808K 2.09% 16
2018
Q4 		$3.24M Sell
38,233
-32,192
-46% -$3.43M 1.94% 19
2018
Q3 		$12.1M Sell
70,425
-20,540
-23% -$3.1M 2.59% 11
2018
Q2 		$11.8M Sell
90,965
-38,025
-29% -$4.24M 2.31% 12
2018
Q1 		$13.3M Sell
128,990
-25,586
-17% -$2.53M 2.66% 7
2017
Q4 		$13.2M Sell
154,576
-30,726
-17% -$2.66M 2.23% 15
2017
Q3 		$16.8M Sell
185,302
-9,160
-5% -$725K 2.44% 10
2017
Q2 		$14.7M Sell
194,462
-5,908
-3% -$413K 1.99% 18
2017
Q1 		$13.2M Sell
200,370
-62,916
-24% -$4.14M 1.76% 28
2016
Q4 		$16.7M Buy
263,286
+19,460
+8% +$1.23M 2.24% 18
2016
Q3 		$14.6M Buy
243,826
+149,299
+158% +$11M 2.23% 20
2016
Q2 		$7.03M Sell
94,527
-69,401
-42% -$5.15M 1.21% 41
2016
Q1 		$11M Buy
163,928
+67,261
+70% +$4.09M 1.89% 23
2015
Q4 		$6.54M Buy
96,667
+46,988
+95% +$2.9M 1.41% 38
2015
Q3 		$2.65M Buy
+49,679
New +$3.01M 0.95% 41

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Falcon Point Capital's LGND Position: Q3 2020 in Review

Falcon Point Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 4,602 shares — an estimated $321K sold.

Falcon Point Capital first reported a position in LGND in Q3 2015 and held it in 20 quarters. The position peaked at $16.8M in Q3 2017. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

  • Falcon Point Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Falcon Point Capital sold 4,602 Ligand Pharmaceuticals shares in Q3 2020, an estimated $321K.
  • Falcon Point Capital first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 20 quarters.
  • Falcon Point Capital's Ligand Pharmaceuticals position peaked at $16.8M in Q3 2017.
  • 252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Falcon Point Capital's 13F filing for Q3 2020, filed 22 Oct 2020.